\"Genome sequencing\" redirects here. For the sequencing only of DNA, see DNA sequencing. <\/p>\n
Whole genome sequencing (also known as WGS, full genome sequencing, complete genome sequencing, or entire genome sequencing) is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast. <\/p>\n
Whole genome sequencing should not be confused with DNA profiling, which only determines the likelihood that genetic material came from a particular individual or group, and does not contain additional information on genetic relationships, origin or susceptibility to specific diseases.[2] Also unlike full genome sequencing, SNP genotyping covers less than 0.1% of the genome. Almost all truly complete genomes are of microbes; the term \"full genome\" is thus sometimes used loosely to mean \"greater than 95%\". The remainder of this article focuses on nearly complete human genomes. <\/p>\n
High-throughput genome sequencing technologies have largely been used as a research tool and are currently being introduced in the clinics.[3][4][5] In the future of personalized medicine, whole genome sequence data will be an important tool to guide therapeutic intervention.[6] The tool of gene sequencing at SNP level is also used to pinpoint functional variants from association studies and improve the knowledge available to researchers interested in evolutionary biology, and hence may lay the foundation for predicting disease susceptibility and drug response. <\/p>\n
The shift from manual DNA sequencing methods such as Maxam-Gilbert sequencing and Sanger sequencing in the 1970s and 1980s to more rapid, automated sequencing methods in the 1990s played a crucial role in giving scientists the ability to sequence whole genomes.[8]Haemophilus influenzae, a commensal bacterium which resides in the human respiratory tract was the first organism to have its entire genome sequenced (Figure 2.1). The entire genome of this bacterium was published in 1995.[9] The genomes of H. influenzae, other Bacteria, and some Archaea were the first to be sequenced - largely due to their small genome size. H. influenzae has a genome of 1,830,140 base pairs of DNA.[9] In contrast, eukaryotes, both unicellular and multicellular such as Amoeba dubia and humans (Homo sapiens) respectively, have much larger genomes (see C-value paradox).[10]Amoeba dubia has a genome of 700 billion nucleotide pairs spread across thousands of chromosomes.[11] Humans contain fewer nucleotide pairs (about 3.2 billion in each germ cell - note the exact size of the human genome is still being revised) than A. dubia however their genome size far outweighs the genome size of individual bacteria.[12] <\/p>\n
The first bacterial and archaeal genomes, including that of H. influenzae, were sequenced by Shotgun sequencing.[9] In 1996, the first eukaryotic genome ( the yeast Saccharomyces cerevisiae) was sequenced. S. cerevisiae, a model organism in biology has a genome of only around 12 million nucleotide pairs,[13] and was the first unicellular eukaryote to have its whole genome sequenced. The first multicellular eukaryote, and animal, to have its whole genome sequenced was the nematode worm: Caenorhabditis elegans in 1998.[14] Eukaryotic genomes are sequenced by several methods including Shotgun sequencing of short DNA fragments and sequencing of larger DNA clones from DNA libraries (see library (biology)) such as Bacterial artificial chromosomes (BACs) and Yeast artificial chromosomes (YACs).[15] <\/p>\n
In 1999, the entire DNA sequence of human chromosome 22, the shortest human autosome, was published.[16] By the year 2000, the second animal and second invertebrate (yet first insect) genome was sequenced - that of the fruit fly Drosophila melanogaster - a popular choice of model organism in experimental research.[17] The first plant genome - that of the model organism Arabidopsis thaliana - was also fully sequenced by 2000.[18] By 2001, a draft of the entire human genome sequence was published.[19] The genome of the laboratory mouse Mus musculus was completed in 2002.[20] <\/p>\n
In 2004, the Human Genome Project published the human genome.[21] <\/p>\n
Currently, thousands of genomes have been sequenced. <\/p>\n
Almost any biological sample containing a full copy of the DNAeven a very small amount of DNA or ancient DNAcan provide the genetic material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, hair (as long as the hair contains a hair follicle), seeds, plant leaves, or anything else that has DNA-containing cells. <\/p>\n
The genome sequence of a single cell selected from a mixed population of cells can be determined using techniques of single cell genome sequencing. This has important advantages in environmental microbiology in cases where a single cell of a particular microorganism species can be isolated from a mixed population by microscopy on the basis of its morphological or other distinguishing characteristics. In such cases the normally necessary steps of isolation and growth of the organism in culture may be omitted, thus allowing the sequencing of a much greater spectrum of organism genomes.[22] <\/p>\n
Single cell genome sequencing is being tested as a method of preimplantation genetic diagnosis, wherein a cell from the embryo created by in vitro fertilization is taken and analyzed before embryo transfer into the uterus.[23] After implantation, cell-free fetal DNA can be taken by simple venipuncture from the mother and used for whole genome sequencing of the fetus.[24] <\/p>\n
Sequencing of nearly an entire human genome was first accomplished in 2000 partly through the use of shotgun sequencing technology. While full genome shotgun sequencing for small (40007000 base pair) genomes was already in use in 1979,[25] broader application benefited from pairwise end sequencing, known colloquially as double-barrel shotgun sequencing. As sequencing projects began to take on longer and more complicated genomes, multiple groups began to realize that useful information could be obtained by sequencing both ends of a fragment of DNA. Although sequencing both ends of the same fragment and keeping track of the paired data was more cumbersome than sequencing a single end of two distinct fragments, the knowledge that the two sequences were oriented in opposite directions and were about the length of a fragment apart from each other was valuable in reconstructing the sequence of the original target fragment. <\/p>\n
The first published description of the use of paired ends was in 1990 as part of the sequencing of the human HPRT locus,[26] although the use of paired ends was limited to closing gaps after the application of a traditional shotgun sequencing approach. The first theoretical description of a pure pairwise end sequencing strategy, assuming fragments of constant length, was in 1991.[27] In 1995 the innovation of using fragments of varying sizes was introduced,[28] and demonstrated that a pure pairwise end-sequencing strategy would be possible on large targets. The strategy was subsequently adopted by The Institute for Genomic Research (TIGR) to sequence the entire genome of the bacterium Haemophilus influenzae in 1995,[29] and then by Celera Genomics to sequence the entire fruit fly genome in 2000,[30] and subsequently the entire human genome. Applied Biosystems, now called Life Technologies, manufactured the automated capillary sequencers utilized by both Celera Genomics and The Human Genome Project. <\/p>\n
While capillary sequencing was the first approach to successfully sequence a nearly full human genome, it is still too expensive and takes too long for commercial purposes. Since 2005 capillary sequencing has been progressively displaced by next-generation sequencing technologies such as Illumina dye sequencing, pyrosequencing, and SMRT sequencing.[31] All of these technologies continue to employ the basic shotgun strategy, namely, parallelization and template generation via genome fragmentation. <\/p>\n
Other technologies are emerging, including nanopore technology. Though nanopore sequencing technology is still being refined, its portability and potential capability of generating long reads are of relevance to whole-genome sequencing applications.[32] <\/p>\n
In principle, full genome sequencing can provide raw data on all six billion nucleotides in an individual's DNA. However, it does not provide an analysis of what that information means or how it might be utilized in various clinical applications, such as in medicine to help prevent disease. Work toward that goal is continuously moving forward. <\/p>\n
Because sequencing generates a lot of data (for example, there are approximately six billion base pairs in each human diploid genome), its output is stored electronically and requires a large amount of computing power and storage capacity. Full genome sequencing would have been nearly impossible before the advent of the microprocessor, computers, and the Information Age. <\/p>\n
A 2015 study[33] done at Children's Mercy Hospital in Kansas City detailed the use of full genome sequencing including full analysis. The process took a record breaking 26 hours[34] and was done using Illumina HiSeq machines, the Edico Genome Dragen Processor, and several custom designed software packages. Most of this acceleration was achieved using the newly developed Dragen Processor which brought the analysis time down from 15 hours to 40 minutes. <\/p>\n
A number of public and private companies are competing to develop a full genome sequencing platform that is commercially robust for both research and clinical use,[35] including Illumina,[36]Knome,[37]Sequenom,[38]454 Life Sciences,[39] Pacific Biosciences,[40]Complete Genomics,[41]Helicos Biosciences,[42]GE Global Research (General Electric), Affymetrix, IBM, Intelligent Bio-Systems,[43] Life Technologies and Oxford Nanopore Technologies.[44] These companies are heavily financed and backed by venture capitalists, hedge funds, and investment banks.[45][46] <\/p>\n
In October 2006, the X Prize Foundation, working in collaboration with the J. Craig Venter Science Foundation, established the Archon X Prize for Genomics,[47] intending to award US$10million to \"the first Team that can build a device and use it to sequence 100 human genomes within 10 days or less, with an accuracy of no more than one error in every 1,000,000 bases sequenced, with sequences accurately covering at least 98% of the genome, and at a recurring cost of no more than $1,000per genome\".[48] An error rate of 1in 1,000,000bases, out of a total of approximately six billion bases in the human diploid genome, would mean about 6,000errors per genome. The error rates required for widespread clinical use, such as predictive medicine[49] is currently set by over 1,400 clinical single gene sequencing tests[50] (for example, errors in BRCA1 gene for breast cancer risk analysis). <\/p>\n
The Archon X Prize for Genomics was cancelled in 2013, before its official start date.[51][52] <\/p>\n
In 2007, Applied Biosystems started selling a new type of sequencer called SOLiD System.[53] The technology allowed users to sequence 60 gigabases per run.[54] <\/p>\n
In June 2009, Illumina announced that they were launching their own Personal Full Genome Sequencing Service at a depth of 30 for $48,000 per genome.[55][56] <\/p>\n
In August 2009, the founder of Helicos Biosciences, Stephen Quake, stated that using the company's Single Molecule Sequencer he sequenced his own full genome for less than $50,000.[57] <\/p>\n
In November 2009, Complete Genomics published a peer-reviewed paper in Science demonstrating its ability to sequence a complete human genome for $1,700.[58][59] <\/p>\n
In May 2011, Illumina lowered its Full Genome Sequencing service to $5,000 per human genome, or $4,000 if ordering 50 or more.[60] Helicos Biosciences, Pacific Biosciences, Complete Genomics, Illumina, Sequenom, ION Torrent Systems, Halcyon Molecular, NABsys, IBM, and GE Global appear to all be going head to head in the race to commercialize full genome sequencing.[31][61] <\/p>\n
A series of publications in 2012 showed the utility of SMRT sequencing from Pacific Biosciences in generating full genome sequences with de novo assembly.[62] <\/p>\n
With sequencing costs declining, a number of companies began claiming that their equipment would soon achieve the $1,000 genome: these companies included Life Technologies in January 2012,[63]Oxford Nanopore Technologies in February 2012[64] and Illumina in February 2014.[65][66] <\/p>\n
However, as of 2015, the NHGRI estimates the cost of obtaining a whole-genome sequence at around $1,500.[67] <\/p>\n
Full genome sequencing provides information on a genome that is orders of magnitude larger than that provided by the previous leader in genotyping technology, DNA arrays. For humans, DNA arrays currently provide genotypic information on up to one million genetic variants,[68][69][70] while full genome sequencing will provide information on all six billion bases in the human genome, or 3,000times more data. Because of this, full genome sequencing is considered a disruptive innovation to the DNA array markets as the accuracy of both range from 99.98% to 99.999% (in non-repetitive DNA regions) and their consumables cost of $5000 per 6 billion base pairs is competitive (for some applications) with DNA arrays ($500per 1 million basepairs).[39]Agilent, another established DNA array manufacturer, is working on targeted (selective region) genome sequencing technologies.[71] It is thought that Affymetrix, the pioneer of array technology in the 1990s, has fallen behind due to significant corporate and stock turbulence and is currently not working on any known full genome sequencing approach.[72][73][74] It is unknown what will happen to the DNA array market once full genome sequencing becomes commercially widespread, especially as companies and laboratories providing this disruptive technology start to realize economies of scale. It is postulated, however, that this new technology may significantly diminish the total market size for arrays and any other sequencing technology once it becomes commonplace for individuals and newborns to have their full genomes sequenced.[75] <\/p>\n
Whole genome sequencing has established the mutation frequency for whole human genomes. The mutation frequency in the whole genome between generations for humans (parent to child) is about 70 new mutations per generation.[76][77] An even lower level of variation was found comparing whole genome sequencing in blood cells for a pair of monozygotic (identical twins) 100-year-old centenarians.[78] Only 8 somatic differences were found, though somatic variation occurring in less than 20% of blood cells would be undetected. <\/p>\n
In the specifically protein coding regions of the human genome, it is estimated that there are about 0.35 mutations that would change the protein sequence between parent\/child generations (less than one mutated protein per generation).[79] <\/p>\n
In cancer, mutation frequencies are much higher, due to genome instability. This frequency can further depend on patient age, exposure to DNA damaging agents (such as UV-irradiation or components of tobacco smoke) and the activity\/inactivity of DNA repair mechanisms.[80] Furthermore, mutation frequency can vary between cancer types: in germline cells, mutation rates occur at approximately 0.023 mutations per megabase, but this number is much higher in breast cancer (1.18-1.66 mutations per Mb), in lung cancer (17.7) or in melanomas (~33).[81] <\/p>\n
Inexpensive, time-efficient full genome sequencing will be a major accomplishment not only for the field of genomics, but for the entire human civilization because, for the first time, individuals will be able to have their entire genome sequenced. Utilizing this information, it is speculated that health care professionals, such as physicians and genetic counselors, will eventually be able to use genomic information to predict what diseases a person may get in the future and attempt to either minimize the impact of that disease or avoid it altogether through the implementation of personalized, preventive medicine. Full genome sequencing will allow health care professionals to analyze the entire human genome of an individual and therefore detect all disease-related genetic variants, regardless of the genetic variant's prevalence or frequency. This will enable the rapidly emerging medical fields of predictive medicine and personalized medicine and will mark a significant leap forward for the clinical genetic revolution. Full genome sequencing is clearly of great importance for research into the basis of genetic disease and has shown significant benefit to a subset of individuals with rare disease in the clinical setting.[82][83][84][85] Illumina's CEO, Jay Flatley, stated in February 2009 that \"A complete DNA read-out for every newborn will be technically feasible and affordable in less than five years, promising a revolution in healthcare\" and that \"by 2019 it will have become routine to map infants' genes when they are born\".[86] This potential use of genome sequencing is highly controversial, as it runs counter to established ethical norms for predictive genetic testing of asymptomatic minors that have been well established in the fields of medical genetics and genetic counseling.[87][88][89][90] The traditional guidelines for genetic testing have been developed over the course of several decades since it first became possible to test for genetic markers associated with disease, prior to the advent of cost-effective, comprehensive genetic screening. It is established that norms, such as in the sciences and the field of genetics, are subject to change and evolve over time.[91][92] It is unknown whether traditional norms practiced in medical genetics today will be altered by new technological advancements such as full genome sequencing. <\/p>\n
In March 2010, researchers from the Medical College of Wisconsin announced the first successful use of whole-genome sequencing to inform the treatment of a patient.[93][94] <\/p>\n
Currently available newborn screening for childhood diseases allows detection of rare disorders that can be prevented or better treated by early detection and intervention. Specific genetic tests are also available to determine an etiology when a child's symptoms appear to have a genetic basis. Full genome sequencing, in addition has the potential to reveal a large amount of information (such as carrier status for autosomal recessive disorders, genetic risk factors for complex adult-onset diseases, and other predictive medical and non-medical information) that is currently not completely understood, may not be clinically useful to the child during childhood, and may not necessarily be wanted by the individual upon reaching adulthood.[95] In addition to predicting disease risk in childhood, genetic testing may have other benefits (such as discovery of non-paternity) but may also have potential downsides (genetic discrimination, loss of anonymity, and psychological impacts).[96] Many publications regarding ethical guidelines for predictive genetic testing of asymptomatic minors may therefore have more to do with protecting minors and preserving the individual's privacy and autonomy to know or not to know their genetic information, than with the technology that makes the tests themselves possible.[97] <\/p>\n
Due to recent cost reductions (see above) whole genome sequencing has become a realistic application in DNA diagnostics. In 2013, the 3Gb-TEST consortium obtained funding from the European Union to prepare the health care system for these innovations in DNA diagnostics.[98][99]Quality assessment schemes, Health technology assessment and guidelines have to be in place. The 3Gb-TEST consortium has identified the analysis and interpretation of sequence data as the most complicated step in the diagnostic process.[100] At the Consortium meeting in Athens in September 2014, the Consortium coined the word genotranslation for this crucial step. This step leads to a so-called genoreport. Guidelines are needed to determine the required content of these reports. <\/p>\n
The majority of ethicists insist that the privacy of individuals undergoing genetic testing must be protected under all circumstances.[101] Data obtained from whole genome sequencing can not only reveal much information about the individual who is the source of DNA, but it can also reveal much probabilistic information about the DNA sequence of close genetic relatives.[102] Furthermore, the data obtained from whole genome sequencing can also reveal much useful predictive information about the relatives present and future health risks.[103] This raises important questions about what obligations, if any, are owed to the family members of the individuals who are undergoing genetic testing. In the Western\/European society, tested individuals are usually encouraged to share important information on the genetic diagnosis with their close relatives since the importance of the genetic diagnosis for offspring and other close relatives is usually one of the reasons for seeking a genetic testing in the first place.[101] Nevertheless, a major ethical dilemma can develop when the patients refuse to share information on a diagnosis that is made for serious genetic disorder that is highly preventable and where there is a high risk to relatives carrying the same disease mutation.[102] Under such circumstances, the clinician may suspect that the relatives would rather know of the diagnosis and hence the clinician can face a conflict of interest with respect to patient-doctor confidentiality.[102] <\/p>\n
Another major privacy concern is the scientific need to put information on patient's genotypes and phenotypes into the public scientific databases such as the locus specific databases.[102] Although only anonymous patient data are submitted to the locus specific databases, patients might still be identifiable by their relatives in the case of finding a rare disease or a rare missense mutation.[102] <\/p>\n
The first nearly complete human genomes sequenced were two caucasians in 2007 (J. Craig Venter at 7.5-fold coverage,[104][105][106] and James Watson at 7.4-fold).[107][108][109] This was followed in 2008 by sequencing of an anonymous Han Chinese man (at 36-fold),[110] a Yoruban man from Nigeria (at 30-fold),[111] and a female caucasian Leukemia patient (at 33 and 14-fold coverage for tumor and normal tissues).[112]Steve Jobs was among the first 20 people to have their whole genome sequenced, reportedly for the cost of $100,000.[113] As of June 2012[update], there are 69 nearly complete human genomes publicly available.[114]Commercialization of full genome sequencing is in an early stage and growing rapidly. <\/p>\n
<\/p>\n
Continue reading here: \"Genome sequencing\" redirects here. For the sequencing only of DNA, see DNA sequencing Continue reading
\nWhole genome sequencing - Wikipedia<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"